Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epinephrine bronchodilators retain FDA essential-use designation allowing CFCs -- ANPR.

This article was originally published in The Tan Sheet

Executive Summary

EPINEPHRINE BRONCHODILATOR PRODUCTS RETAIN ESSENTIAL-USE DESIGNATION because epinephrine is the "only active moiety" used in OTC drug products containing chlorofluorocarbon propellants, FDA observes in a March 6 advance notice of proposed rulemaking on CFCs in self-pressurized container whose uses are no longer essential. "These OTC drug products are available to patients who may not have access to prescription drugs. Therefore," the ANPR states, "FDA has tentatively determined that prescription drugs should not be considered as alternatives to drug products containing epinephrine."

You may also be interested in...



CFC-Containing MDIs Are "Essential" Until Multiple Alternatives Available

More than one CFC-free product alternative must be available before FDA phases out a CFC-containing metered dose inhaler that is available under multiple NDAs or in multiple strengths, the agency suggests in a proposed rule on ozone depleting substances (ODS) published in the Sept. 1 Federal Register.

CFC-Containing MDIs Are "Essential" Until Multiple Alternatives Available

More than one CFC-free product alternative must be available before FDA phases out a CFC-containing metered dose inhaler that is available under multiple NDAs or in multiple strengths, the agency suggests in a proposed rule on ozone depleting substances (ODS) published in the Sept. 1 Federal Register.

CFC-Containing MDIs Are "Essential" Until Multiple Alternatives Available

More than one CFC-free product alternative must be available before FDA phases out a CFC-containing metered dose inhaler that is available under multiple NDAs or in multiple strengths, the agency suggests in a proposed rule on ozone depleting substances (ODS) published in the Sept. 1 Federal Register.

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel